Last updated: July 27, 2026
What clinical trials exist for hydrocodone bitartrate right now?
Hydrocodone bitartrate is an opioid analgesic active in U.S. therapy, typically developed and studied through product-specific programs tied to a branded NDA/ANDA portfolio rather than through a single “drug-wide” clinical program. Clinical-trial volume and relevance are therefore driven by the exact marketed dosage form (for example, immediate-release vs extended-release, combination vs single-entity) and the specific sponsor/label.
Clinical trials update (what matters for decision-making)
- Interventional efficacy and safety studies: Most hydrocodone bitartrate clinical work is conducted to support label claims and product formulation changes, including:
- analgesic performance and onset of action,
- opioid-related adverse events (respiratory depression, sedation, constipation),
- abuse-deterrence characterization where relevant to the dosage form.
- PK/BE studies for generics and reformulations: These are often the dominant trial activity when branded exclusivity periods near end, since manufacturers run bioequivalence studies tied to generic/authorized generic entry strategy.
- Pediatric and post-marketing commitments: Opioid programs may include post-marketing safety studies and labeling updates, depending on the original NDA terms.
High-signal readouts to track in sponsor disclosures
- Updated FDA labeling revisions tied to safety communications.
- Post-marketing safety study enrollment status and final results (respiratory risk, abuse liability signals).
- Completion dates for any sponsor-run reformulation trials and the resulting supplemental NDA status.
Which companies are developing hydrocodone bitartrate products and what are the trial stages?
Hydrocodone bitartrate development is typically split between:
- Original NDA sponsors for the marketed product strength/dosage form,
- generic entrants running bioequivalence or clinical bridge protocols,
- risk-management stakeholders supporting REMS-related initiatives for opioid analgesics.
For business and litigation planning, the critical “company” question is not only who is running trials, but who controls:
- the Orange Book listings (drug substance and formulation patents),
- the pivotal/supplemental NDA history that locks in exclusivity and patent coverage,
- the likely ANDA filer set for Paragraph IV challenges.
What is the Orange Book status of hydrocodone bitartrate?
Orange Book status is determined by:
- active NDA entries for hydrocodone bitartrate,
- listed patents (composition, formulation, method-of-use, and/or manufacturing),
- exclusivity codes (if any) tied to the NDA.
Practical implication
- For opioids with established brands, the “Orange Book status” question typically resolves to: which patents are still listed as of the present date, which are formulation vs method-of-use, and which are the likely targets for Paragraph IV certification.
When does hydrocodone bitartrate lose exclusivity and how many patents are still listed?
Exclusivity and patent lifetimes drive the probability-weighted generic entry window.
Decision-grade framework
- Patent expiration controls the end of enforceable exclusivity for specific claims.
- Regulatory exclusivities (3-year, 5-year, 7-year) apply only in limited scenarios and are generally product-entry gating rather than claim gating.
What to model in projections
- Earliest first generic launch date: based on the last expiring listed patent that blocks generic marketing for the relevant product/dosage form.
- Settlement/launch timing: if a Paragraph IV challenge leads to a settlement, the entry date may move to a later agreed trigger.
- Multiple patent expirations: brands often preserve staggered protection by listing different claim sets across strengths and dosage forms.
What patents protect hydrocodone bitartrate formulations, strengths, and delivery systems?
Patent estates for hydrocodone bitartrate products commonly include:
- Composition-of-matter and salt form coverage (hydrocodone bitartrate),
- Formulation patents (matrix, coating, excipients, release profile if applicable),
- Manufacturing process patents (granulation, blending, compression, polymorph control),
- Method-of-use patents (less common for mature opioid analgesics, but present in certain label-expansion contexts),
- Packaging/use patents where applicable.
How this affects generic risk
- If formulation patents dominate, generic risk centers on whether an ANDA can use a “carve-out” design or an alternative excipient system without infringing.
- If method-of-use is dominant, ANDA labels may need carve-outs or narrow indications.
What generic entry risks exist for hydrocodone bitartrate ANDAs?
Generic entry risk for hydrocodone bitartrate depends on the Orange Book patent list and certification path.
Key risk vectors
- Paragraph IV litigation: Generic filers challenge at least one listed patent. Courts then determine whether the patents are invalid or not infringed.
- Design-around feasibility: Formulation patents may be bypassed by changing release mechanics or excipient systems, depending on claim breadth.
- Regulatory labeling constraints: Even if patent workarounds exist, labeling carve-outs can delay effective substitution.
Which patent litigation affects hydrocodone bitartrate and what is the status of cases?
The litigation question is central for market projections because it sets:
- timing certainty of generic entry,
- likelihood of settlement-driven “at-risk” launches,
- potential injunction exposure.
What to monitor for each case
- Case caption and venue,
- filing date and asserted patents,
- court rulings on infringement and invalidity,
- dates tied to appeal and final mandate,
- settlement terms that may include agreed launch dates or “no-at-risk” provisions.
Do hydrocodone bitartrate clinical trials signal changes in abuse-deterrence or safety labeling?
For opioid products, changes in clinical or post-marketing data can shift:
- risk mitigation steps in REMS execution,
- prescriber communication language,
- potential changes in dosage selection and warnings.
Market impact linkage
- tighter labeling can reduce substitutability and slow generic uptake,
- safety communications can shift payer formularies and limit certain strengths.
How does hydrocodone bitartrate market performance compare with other hydrocodone products?
Hydrocodone bitartrate competes within the broader hydrocodone/acetaminophen and hydrocodone single-entity ecosystem depending on the exact NDA product composition.
Competitive comparison axes
- Form factor: immediate-release vs extended-release drives payer preference and clinician prescribing behavior.
- Therapeutic positioning: acute pain vs chronic pain label language influences utilization.
- Generic availability: earlier ANDA launches typically compress brand price and shift share.
What is the current market size and pricing outlook for hydrocodone bitartrate?
A full market projection requires confirmed U.S. product-level data (NDC-level revenue, volume, and WAC and net price). Without that product-specific baseline, projections are not actionable for capital allocation or litigation settlement modeling.
Decision-grade proxy approach (what to model, once product-level data is available)
- brand net sales vs time-on-market for the last generics,
- average daily dose distribution across strengths,
- payer contract structure and step edits,
- substitution rates post-first generic launch.
When is hydrocodone bitartrate expected to face first generic competition under FDA rules?
For FDA entry timing, the key gating is:
- patent expiration date(s) for the relevant product,
- whether Paragraph IV litigation leads to a 30-month stay,
- any settlement that delays or permits launch.
Launch timing logic
- Generic filer submits ANDA with Paragraph IV certification.
- Litigation triggers 30-month stay or ends earlier if final judgments occur.
- If settlement is reached, a mutually agreed launch date replaces trial-driven timing.
How does FDA regulatory pathway status affect hydrocodone bitartrate commercialization?
Hydrocodone bitartrate’s commercialization depends on:
- whether the marketed product is under ongoing post-approval requirements,
- whether label updates influence prescribing,
- whether safety-related FDA actions affect manufacturing and distribution.
Regulatory timeline items that drive commercialization
- manufacturing changes and comparability protocols,
- REMS execution metrics,
- post-marketing commitments.
How strong is the patent estate for hydrocodone bitartrate versus nearby opioid analgesics?
Patent strength is best evaluated by:
- number of listed patents active on the Orange Book,
- claim diversity (composition plus multiple formulation/process patents increases barrier),
- history of litigation outcomes (where available),
- likelihood of design-around.
Business conclusion format
- Strongest estates feature multiple independently enforceable claim sets and broad formulation coverage.
- Weaker estates show narrow claims and easy design-around pathways.
What formulations are protected by hydrocodone bitartrate patents?
Formulation protection usually targets:
- specific excipient combinations,
- release rate modifiers and coatings,
- manufacturing parameters that define critical quality attributes,
- dosage form attributes tied to stability and dissolution specifications.
Why this matters
- Formulation patents reduce generic substitutability if the generic must match a tightly defined release and dissolution profile.
What method-of-use patents cover hydrocodone bitartrate indications?
Method-of-use patents are less common in older opioid analgesics than in newer specialty therapeutics, but they can appear with label expansions or sponsor-driven clinical characterization.
If present, model:
- claim scope relative to label wording,
- whether an ANDA could use a narrower indication carve-out,
- whether infringement would hinge on typical prescribing.
What settlement agreements or licensing deals influence hydrocodone bitartrate generic launch dates?
Settlement terms often dictate:
- agreed launch windows,
- “no challenge” agreements on certain patents,
- cross-licenses if the branded company has relevant process or formulation improvements for manufacturing.
Market relevance
- settlement timing is frequently the dominant determinant of the practical generic market entry date.
Key Takeaways
- Hydrocodone bitartrate’s clinical-trial activity is largely product-specific and split between label-support studies and reformulation or bioequivalence programs.
- Exclusivity and generic entry timing depend on Orange Book patent listings for the exact hydrocodone bitartrate NDA product and dosage form, plus any Paragraph IV litigation stay or settlement.
- Market projections hinge on (i) the last expiring enforceable patent for each strength/dosage form, (ii) whether litigation pushes launches beyond expected expiration, and (iii) substitution speed after first generic entry.
- Patent strength is driven by claim diversity across composition, formulation, and process, which determines generic design-around feasibility.
FAQs
- How do I identify the exact Orange Book NDA entry for hydrocodone bitartrate by NDC?
- What certifications do ANDAs for hydrocodone bitartrate typically use (Paragraph III vs IV) and how does that affect timelines?
- Do hydrocodone bitartrate generic launches depend more on formulation patents or method-of-use patents?
- How does a 30-month stay apply to opioid ANDA Paragraph IV litigation for hydrocodone bitartrate?
- What signals in FDA labeling or post-marketing reports most affect payer access for hydrocodone bitartrate products?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Trials Snapshots. U.S. Food and Drug Administration.
